STAT
@statnews
Reporting from the frontiers of health & medicine.
Sign up for any of our newsletters here:
4.7K Following 165.3K Followers
#STATSummit# week is here. More than 400 leaders will be in the room in Boston, with hundreds more joining online.
Don’t miss two days of live conversations with the people at the center of this year’s biggest stories. There’s still time to join us:
Show more
Just 40 percent of Americans reported a lot of confidence in U.S. hospitals and health clinics, the same proportion as in Portugal and Uruguay.
In a letter, 12-year-old Brecken urged Novartis to make the Duchenne therapy he received available to patients like his friend Yannick:
"It is getting hard for him to throw the ball for his dog Rosie and drink a glass of water. This makes me sad."
Show more
Research shows that the U.S. pays, on average, anywhere from three to four times as much for brand-name drugs compared with other wealthy countries.
But a breaking point is imminent, one that makes government intervention to curb health care costs inevitable, experts insist.
Show more
U.S. health spending is on pace to cost almost $16,500 per person this year.
And the biggest portion of an employer's health spending — even for the largest corporations in the country — has remained the same since the 1980s:
Show more
Steven Quay, a biopharmaceutical executive with no background in infectious diseases, is no longer being considered for director of the National Institute for Allergy and Infectious Diseases.
Show more
The AHA is once again suing the Trump administration over its plan to revamp a federal drug discount program into one that provides after-the-fact rebates instead of upfront discounts.
Show more
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
The gifts and payments that doctors receive from drugmakers increased inappropriate prescribing, likely leading to rising health care costs, according to a new review.
Life Biosciences said yesterday that three glaucoma patients have now received a single injection of its experimental cellular reprogramming drug, with no serious adverse events.
Show more
There's no denying that MAHA made a splash when it first brought into MAGA by RFK Jr. But with the midterms approaching, the question is: Can the movement survive an election focused on affordability amid slow progress? w/ @isabellacueto @_daniel_payne
Show more
The federal government has released new quality ratings for Medicare Advantage insurers for 2027, with Humana emerging as the biggest winner. But deep uncertainty remains around Medicare Advantage quality measures,…
Show more
Three glaucoma patients have received Life Biosciences' cellular reprogramming drug, with no serious adverse events.
The drug is the first human test of the theory that giving a precise cocktail of proteins could rejuvenate cells back to a younger state.
Show more
Once described as obesity medicines for ‘patients,’ GLP-1s are increasingly lifestyle drugs for ‘customers’
Smart story from @elaineywchen
via @statnews
The Trump administration wants to make three big changes to the U.S. Census, including eliminating questions about race, ethnicity, and sexual orientation and excluding anyone who is not a citizen…
Show more
The FDA flagged a potential safety signal after four patient deaths in a trial testing a schizophrenia drug, Argenx faces an unusual setback, and more pharma news.
A new bill in Congress seeks to scrap the No Surprises Act’s costly arbitration process, but already it faces staunch opposition from provider groups, who say it gives more power to health insurers via @statnews
Show more
MAHA activists have claimed to lead a revolution in American politics.
Now, they meet disappointing midterm realities.
Tomorrow at 1 p.m. ET: Biosimilars: Have We Reached an Inflection Point?
STAT’s Ed Silverman will moderate a virtual conversation with experts about the next wave of biosimilars, shifting FDA policies and what’s next for the market. Join us online.
Show more
Members of Congress push back on plan to create a commission of political appointees to review NIH grants
